Cardiac repair and the putative role of stem cells

Journal of Molecular and Cellular Cardiology

Volumn 128, Issue , 2019, Pages 96-104

  Buja, L Maximilian ^a,b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Cardiac regeneration; Cardiac repair; Cardiac stem cells; Clinical trials

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

CARDIAC MUSCLE CELL; CARDIAC REGENERATION; CARDIAC STEM CELL; CELL DIVISION; CELL EXPANSION; CELL POPULATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELL VIABILITY; DISEASE COURSE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; ISCHEMIA; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; ANIMAL; CARDIAC MUSCLE; GENETICS; HEART DISEASE; METABOLISM; PATHOLOGY; PROCEDURES; REGENERATION; STEM CELL; TRANSPLANTATION;

ANIMALS; HEART DISEASES; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 85060604481     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2019.01.022     Document Type: Review

References (112)

1. Linzbach, A.J., Heart failure from the point of view of quantitative anatomy. Am. J. Cardiol. 5 (1960), 370–382.
2. Hort, W., Quantitative morphology and structural dynamics of the myocardium. Bajusz, E., Jasmin, G., (eds.) Methods and Achievements in Experimental Pathology, Vol. 5. Functional Morphology of the Heart, Methods and Achievements in Experimental Pathology, 1971, Karger, Basel, 3–21.
3. Kajstura, J., Leri, A., Finato, N., et al. Myocyte proliferation in end-stage cardiac failure in humans. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 8801–8805.
4. Beltrami, A.P., Urbanek, K., Kajstura, J., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N. Engl. J. Med. 344 (2001), 1750–1757.
5. Anversa, P., Nadal-Ginard, B., Myocyte renewal and ventricular remodelling. Nature 415 (2002), 240–243.
6. Leri, A., Kajstura, J., Anversa, P., Cardiac stem cells and mechanisms of myocardial regeneration. Physiol. Rev. 85 (2005), 1373–1416.
7. Hierlihy, A.M., Seale, P., Lobe, C.G., Rudnicki, M.A., Megeney, L.A., The post-natal heart contains a myocardial stem cell population. FEBS Lett. 530 (2002), 239–243.
8. Messina, E., De Angelis, L., Frati, G., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95 (2004), 911–921.
9. Mitalipov, S., Wolf, D., Totipotency, pluripotency and nuclear reprogramming. Adv. Biochem. Eng. Biotechnol. 114 (2009), 185–199.
10. Yang, X.F., Immunology of stem cells and cancer stem cells. Cell Mol. Immunol. 4 (2007), 161–171.
11. Soonpaa, M.H., Field, L.J., Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 272 (1997), H220–H226.
12. Pasumarthi, K.B.S., Field, L.J., Cardiomyocyte cell cycle regulation. Circ. Res. 90 (2002), 1044–1054.
13. Bergmann, O., Bhardwaj, R.D., Bernard, S., Zdunek, S., et al. Evidence for cardiomyocyte renewal in humans. Science 324 (2009), 98–102.
14. Eschenhagen, T., Bolli, R., Braun, T., et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136 (2017), 680–686.
15. Buja, L.M., Vela, D., Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc. Pathol. 17 (2008), 349–374.
16. Buja, L.M., Vela, D., Current status of the role of stem cells in myocardial biology and repair. Cardiovasc. Pathol. 20 (2011), 297–301.
17. Hsieh, P.C., Segers, V.F., Davis, M.E., et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat. Med. 13 (2007), 970–974.
18. Laflamme, M.A., Zbinden, S., Epstein, S.E., Murry, C.E., Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu. Rev. Pathol. Mech. Dis. 2 (2007), 307–339.
19. Prabhu, S.D., Frangogiannisannis, N.G., The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ. Res. 119 (2016), 91–112.
20. Forte, E., Furtado, M.B., Rosenthal, N., The interstitium in cardiac repair: role of the immune cell – stromal interplay. Nat. Rev. Cardiol. 15 (2018), 601–616.
21. Vela, D., Buja, L.M., Quest for the cardiovascular holy grail: mammalian myocardial regeneration. Cardiovasc. Pathol. 17 (2008), 1–5.
22. Westaby, S., Cardiac transplant or rotary blood pump: contemporary evidence. J. Thoracic Cardiovasc. Surg. 145 (2013), 24–31.
23. Barile, L., Lionetti, V., Prometheus's heart: what lies beneath. J. Cell. Mol. Med. 16 (2012), 228–236.
24. Franklin, S., Kimball, T., Rasmussen, T.L., et al. The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. Am. J. Physiol. Heart Circ. Physiol. 311 (2016), H1234–H1247.
25. Wang, J., Liu, S., Heallen, T., Martin, J.F., The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat. Rev. Cardiol. 15 (2018), 672–684.
26. Gilgenkrantz, H., de l'Hortet, A.C., Understanding liver regeneration: from mechanisms to regenerative medicine. Am. J. Pathol. 188 (2018), 1316–1327.
27. Sarkaria, S.M., Decker, M., Lei, Ding L., Bone marrow micro-environment in normal and deranged hematopoiesis: opportunities for regenerative medicine and therapies. BioEssays, 40, 2018, 1700190.
28. Monaco, J.L., Lawrence, W.T., Acute wound healing: an overview. Clin. Plastic Surg. 30 (2003), 1–12.
29. Daley, W.P., Peters, S.B., Larsen, M., Extracellular matrix dynamics in development and regenerative medicine. J. Cell Sci. 121 (2008), 255–264.
30. Braunwald, E., Cell-based therapy in cardiac regeneration: an overview. Circ. Res. 123 (2018), 132–137.
31. Müller, P., Lemcke, H., David, R., Stem cell therapy in heart diseases – cell types, mechanisms and improvement strategies. Cell. Physiol. Biochem. 48 (2018), 2607–2655.
32. Orlic, D., Kajstura, J., Chimenti, S., et al. Bone marrow cells regenerate infarcted myocardium. Nature 410 (2001), 701–705.
33. Jackson, K.A., Majka, S.M., Wang, H., et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. Invest. 107:11 (2001), 1395–1402.
34. Beltrami, A.P., Barlucchi, L., Torella, D., et al. Adult cardiac stem cells are multipotential and support myocardial regeneration. Cell 114 (2003), 763–776.
35. Oh, H., Bradfute, S.B., Gallardo, T.D., et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 12313–12318.
36. Murry, C.E., Soonpaa, M.H., Reinecke, H., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428 (2004), 664–668.
37. Balsam, L.B., Wagers, A.J., Christensen, J.L., Kofidis, T., Weissman, I.L., Robbins, R.C., Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428 (2004), 668–673.
38. Miritsou, M., Jayawardena, T.M., Schmeckpeper, J., Gnecchi, M., Dzau, V.J., Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J. Mol. Cell. Cardiol. 50 (2011), 280–289.
39. Harsdorf, R., Poole-Wilson, P.A., Dietz, R., Regenerative capacity of the myocardium: implications for treatment of heart failure. Lancet 363 (2004), 1306–1313.
40. Murry, C.E., Field, L.J., Menasché P., Cell-based cardiac repair: reflections at the 10-year point. Circulation 112 (2005), 3174–3183.
41. LaFlamme, M.A., Murry, C.E., Regenerating the heart. Nat. Biotechnol. 23 (2005), 845–856.
42. Rubart, M., Field, L.J., Cardiac regeneration: repopulating the heart. Annu. Rev. Physiol. 68 (2006), 29–49.
43. Rubart, M., Field, L.J., Cell-based approach for cardiac repair. Ann. N. Y. Acad. Sci. 1080 (2006), 34–48.
44. Zwetsloot, P.P., Végh, A.M., Jansen of Lorkeers SJ, et al. Cardiac stem cell treatment in myocardial infarction: a systematic review and metaanalysis of preclinical studies. Circ. Res. 118 (2016), 1223–1232.
45. Tompkins, B.A., Balkan, W., Winkler, J., et al. Preclinical studies of stem cell therapy for heart disease. Circ. Res. 122 (2018), 1006–1020.
46. Perin, E.C., Silva, G.V., Assad, J.A.R., Vela, D., Buja, L.M., Sousa, A.L.S., Litovsky, S., Lin, J., Vaughn, W., Coulter, S., Fernandes, M.R., Willerson, J.T., Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J. Mol. Cell. Cardiol. 44 (2008), 486–495.
47. Badr Eslam, R., Croce, K., Mangione, F.M., Musmann, R., Leopold, J.A., Mitchell, R.N., Waxman, A.B., Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension. Cytotherapy 19:6 (2017), 668–679.
48. Vela, D.C., Silva, G.V., Assad, J.A.R., Sousa, A.L.S., Coulter, S., Fernandes, M.R., Perin, E.C., Willerson, J.T., Buja, L.M., Histopathologic study of healing after allogenic mesenchymal stem cell delivery in myocardial infarction in dogs. J. Histochem. Cytochem. 57 (2009), 167–176.
49. Gahremanpour, A., Vela, D., Zheng, Y., Silva, G.V., Fodor, W., Cardoso, C.O., Baimbridge, F., Fernandes, M.R., Buja, L.M., Perin, E.C., Xenotransplantation of human unrestricted somatic stem cells in a pig model of acute myocardial infarction. Xenotransplantation 20 (2013), 110–122.
50. Vela, D., Gahremanpour, A., Buja, L.M., Method for sectioning and sampling hearts for histologic evaluation after delivery of biological agents by transendocardial injection. Cardiovasc. Pathol. 24:5 (2015), 304–309.
51. Poncelet, A.J., Vercruysse, J., Saliez, A., Gianello, P., Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 52 (2007), 783–790.
52. Hashemi, S.M., Ghods, S., Kolodgie, F.D., Parcham-Azad, K., Keane, M., Hamamdzic, D., Young, R., et al. A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur. Heart J. 29 (2008), 251–259.
53. Grinnemo, K.H., Mansson, A., Dellgren, G., Klingberg, D., Wardell, E., Drvota, V., Tammik, C., et al. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J. Thorac. Cardiovasc. Surg. 127 (2004), 1293–1300.
54. Kim, B.O., Tian, H., Prasongsukarn, K., et al. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation 112 (2005), I96–I104.
55. MoelkerAD, BaksT, Weaver, K.M., et al. Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve lv function after myocardial infarction in swine. J. Mol. Cell. Cardiol. 42 (2007), 735–745.
56. Buja, L.M., Vela, D., Immunologic and inflammatory reactions to exogenous stem cells: implications for experimental studies and clinical trials for myocardial repair. J. Am. Coll. Cardiol. 56 (2010), 1693–1700.
57. Huang, X.P., Sun, Z., Miyagi, Y., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122 (2010), 2419–2429.
58. Natsumeda, M., Florea, V., Rieger, A.C., et al. A combination of allogeneic stem cells promotes cardiac regeneration. J. Am. Coll. Cardiol. 70 (2017), 2504–2515.
59. Weil, B.R., Suzuki, G., Leiker, M.M., Fallavollita, J.A., Canty, J.M. Jr., Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ. Res. 117 (2015), 634–644.
60. Gerbin, K.A., Murry, C.E., The winding road to regenerating the human heart. Cardiovasc. Pathol. 24 (2015), 133–140.
61. Liu, Y.W., Chen, B., Yang, X., et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat. Biotechnol. 36 (2018), 597–605.
62. Hatani, T., Funakoshi, S., Deerinck, T.J., Bushong, E.A., Kimura, T., Takeshima, H., Ellisman, M.H., Hoshijima, M., Yoshida, Y., Nano-structural analysis of engrafted human induced pluripotent stem cell-derived cardiomyocytes in mouse hearts using a genetic-probe APEX2. Biochem. Biophys. Res. Commun. 505:4 (2018), 1251–1256.
63. Tsifaki, M., Kelaini, S., Caines, R., Yang, C., Margariti, A., Regenerating the cardiovascular system through cell reprogramming; current approaches and a look into the future. Front Cardiovasc. Med., 5, 2018, 109, 10.3389/fcvm.2018.00109 (eCollection 2018).
64. Martinez, E.C., Kofidis, T., Adult stem cells for cardiac tissue engineering. J. Mol. Cell. Cardiol. 50 (2011), 312–319.
65. Zimmermann, W.H., Embryonic and embryonic-like stem cells in heart muscle engineering. J. Mol. Cell. Cardiol. 50 (2011), 320–326.
66. Iglesias-García, O., Pelacho, B., Prósper, F., Induced pluripotent stem cells as a new strategy for cardiac regeneration and disease modeling. J. Mol. Cell. Cardiol. 62 (2013), 43–50.
67. Perin, E.C., Dohmann, H.F., Borojevic, R., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107:18 (2003), 2294–2302.
68. Perin, E.C., Dohmann, H.F., Borojevic, R., et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110:11 Suppl 1 (2004), II213–8.
69. Dohmann, H.F.R., Perin, E.C., Takiya, C.M., et al. Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation 112 (2005), 521–526.
70. Dimmeler, S., Zeiher, A.M., Schneider, M.D., Unchain my heart: the scientific foundations of cardiac repair. J. Clin. Invest. 115 (2005), 572–583.
71. Mathur, A., Martin, J.F., Stem cells and repair of the heart. Lancet, 2004, 183–192.
72. Caplice, N.M., Deb, A., Myocardial-cell replacement: the science, the clinic and the future. Nat. Clin. Pract. Cardiovasc. Med. 1:2 (2004), 90–95.
73. Simari, R.D., Moyé L.A., Skarlatos, S.I., et al. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J. Cardiovasc. Transl. Res. 3:1 (2010), 30–36.
74. Zhu, W., Zhang, J., Meeting report for the 2017 National Institutes of Health National Heart, Lung, and Blood Institute Progenitor Cell Biology Consortium: Cardiovascular Bioengineering Workshop and Symposium. Circ. Res. 120 (2017), 1709–1712.
75. Gyöngyösi, M., Wojakowski, W., Navarese, E.P., Moye, L.A., on behalf of the ACCRUE investigators, Controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ. Res. 118 (2016), 1254–1263.
76. Martin-Rendon, E., What can systematic reviews tell us about cell therapies for ischemic heart disease?. Circ. Res. 118 (2016), 1264–1272.
77. Sanganalmath, S.K., Bolli, R., Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 113 (2013), 810–834.
78. Vrtovec, B., Cell therapy for nonischemic cardiomyopathy: current status and future prospects. Circ. Res. 122 (2018), 28–30.
79. Willerson, J.T., Taylor, D., Perin, E.C., Till truth makes all things plain: human hearts and stem cells. Circ. Res. 115 (2014), 908–910.
80. Ashur, C., Frishman, W.H., Cardiosphere-derived cells and ischemic heart failure. Cardiol. Rev. 26 (2018), 8–21.
81. Hare, J.M., DL, DiFede, Rieger, A.C., et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J. Am. Col. Cardiol. 69 (2017), 526–537.
82. Tsilimigras, D.I., Oikonomou, E.K., Moris, D., et al. Stem cell therapy for congenital heart disease: a systematic review. Circulation 136 (2017), 2373–2385.
83. Cahill, T.J., Choudhury, R.P., Riley, P.R., Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics. Nat. Rev. Drug Disc. 16 (2017), 699–717.
84. The Lancet Editors, Expression of concern: the SCIPIO trial. Lancet, 383(9925), 2014, 1279.
85. https://www.sciencemag.org/news/2017/04/10-million-settlement-over-alleged-misconduct-boston-heart-stem-cell-lab.
86. https://www.sciencemag.org/news/2018/10/retract-cardiac-stem-cell-papers-harvard-medical-school-says.
87. Notice of retraction. Circulation, 129(16), 2014, e466 (For the article by Kajstura J, et al. (Cardiomyogenesis in the aging and failing human heart. Circulation. 2012;126:1869–1881); an ongoing institutional review by Harvard Medical School and Brigham and Women's Hospital has determined that the data are sufficiently compromised that a retraction is warranted).
88. Myocytes divide after myocardial infarction. N. Engl. J. Med. 344 (2001), 1750–1757 (Quaini F et al. Chimerism of the transplanted heart. N Engl J Med 2002;346:5–15. N Engl J Med. 2018 Oct 17) https://doi.org/10.1056/NEJMe1813801 (Epub ahead of print).
89. Drazen, J.M., Retraction: Kajstura J et al. Evidence for Human Lung Stem Cells. N Engl J Med 2011;364:1795–806. N. Engl. J. Med., 2018, 10.1056/NEJMe1813802 (Epub ahead of print).
90. https://www.nhlbi.nih.gov/news/2018/statement-nhlbi-decision-pause-concert-hf-trial.
91. + cardiac stem cells as regenerative therapy for heart failure). Circ. Res. 122 (2018), 1703–1715.
92. Fung, M., Yuan, Y., Atkins, H., Shi, Q., Bubela, T., Responsible translation of stem cell research: an assessment of clinical trial registration and publications. Stem Cell Rep. 8 (2017), 1190–1201.
93. George, B., Regulations and guidelines governing stem cell based products: clinical considerations. Perspect. Clin. Res., 2011, 94–99.
94. Au, P., Hursh, D.A., Lim, A., et al. FDA oversight of cell therapy clinical trials. Sci. Transl. Med., 149(4), 2012, 149fs31.
95. Tsan, M.F., Measuring the quality and performance of institutional review boards. J. Empir. Res. Hum. Res. Ethics., 2018, 1556264618804686, 10.1177/1556264618804686 (Epub ahead of print).
96. King, N.M., Who's winning the IRB wars? The struggle for the soul of human research. Perspect. Biol. Med. 61:3 (2018), 450–464.
97. Raval, A.N., Kamp, T.J., Hogle, L.F., Cellular therapies for heart disease: unveiling the ethical and public policy challenges. J. Mol. Cell. Cardiol. 45 (2008), 593–601.
98. Kimmelman, J., Heslop, H.E., Sugarman, J., Streder, L., Benvenisty, N., Canefield, T., et al. New ISSCR guidelines: clinical translation of stem cell research. Lancet 387 (2016), 1979–1981.
99. Miller, F.G., Rosenstein, D.L., DeRenzo, E.G., Professional integrity in clinical research. JAMA 280 (1998), 1449–1454.
100. https://celltexbank.com.
101. http://www.fda.gov/forconsumers/consumerupdates/ucm286155.htm.
102. Cianflone, E., Aquila, I., Scalise, M., et al. Molecular basis of functional myogenic specification of bona fide multipotent adult cardiac stem cells. Cell Cycle 17:8 (2018), 927–946.
103. Maroli, G., Braun, T., The complex biology of KIT+ cells in the heart. Nat. Cardiol. Rev. 15 (2018), 443–444.
104. Kanisicak, O., Vagnozzi, R.J., Molkentin, J.D., Identity crisis for regenerative cardiac cKit+cells. Circ. Res. 121 (2017), 1130–1132.
105. Vagnozzi, R.J., Molkentin, J.D., Houser, S.R., New myocyte formation in the adult heart: endogenous sources and therapeutic implications. Circ. Res. 123 (2018), 159–176.
106. Vagnozzi, R.J., Sargent, M.A., Lin, S.C.J., et al. Genetic lineage tracing of Sca-1+ cells reveals endothelial but not myogenic contribution to the murine heart. Circulation, 2018, 10.1161/CIRCULATIONAHA.118.035210 (Epub ahead of print).
107. Li, Y., He, L., Huang, X., et al. Genetic lineage tracing of non-myocyte population by dual recombinases. Circulation, 2018, 10.1161/CIRCULATIONAHA.118.034250 (Epub ahead of print).
108. Bolli, R., Repeated cell therapy: a paradigm shift whose time has come. Circ. Res. 120 (2017), 1072–1074.
109. Wysoczynki, M., Khan, A., Bolli, R., New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ. Res. 123 (2018), 138–158.
110. Hashimoto, H., Olson, E.N., Bassel-Duby, R., Therapeutic approaches for cardiac regeneration and repair. Nat. Rev. Cardiol. 15 (2018), 585–600.
111. Gabisonia, K., Recchia, F.A., Gene therapy for heart failure: new perspectives. Curr. Heart Fail. Rep., 2018, 10.1007/s11897-018-0410-z (Epub ahead of print).
112. El Harane, N., Kervadec, A., Bellamy, V., Pidial, L., Neametalla, H.J., Perier, M.C., et al. Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors. Eur. Heart J. 39:20 (2018), 1835–1847.